Human Cytomegalovirus (HCMV) - specific T-cell response after letermovir prophylaxis is predictive for subsequent HCMV reactivation in haematopoietic stem cell transplant recipients.

[1]  F. Baldanti,et al.  ELISPOT assays with pp65 peptides or whole HCMV antigen are reliable predictors of immune control of HCMV infection in seropositive kidney transplant recipients , 2023, Journal of medical virology.

[2]  G. Papanicolaou,et al.  Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults , 2022, Blood advances.

[3]  J. Serody,et al.  Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. , 2021, Blood cancer discovery.

[4]  J. Schiffer,et al.  Cytomegalovirus-specific T-cell Reconstitution following Letermovir Prophylaxis after Hematopoietic Cell Transplantation. , 2021, Blood.

[5]  D. Lilleri,et al.  Early T cell reconstitution and cytokine profile may help to guide a personalized management of human cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. , 2021, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[6]  F. Baldanti,et al.  Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  F. Baldanti,et al.  Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies , 2019, Clinical transplantation.

[8]  F. Baldanti,et al.  Collaborative national multicenter for the identification of conversion factors from copies/mL to international units/mL for the normalization of HCMV DNA load. , 2019, Diagnostic microbiology and infectious disease.

[9]  F. Baldanti,et al.  Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay , 2019, Journal of immunology research.

[10]  Michael Boeckh,et al.  Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic‐Cell Transplantation , 2017, The New England journal of medicine.

[11]  L. Lekakis,et al.  Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  J. Preiksaitis,et al.  Determination of the Biological Form of Human Cytomegalovirus DNA in the Plasma of Solid-Organ Transplant Recipients , 2017, The Journal of infectious diseases.

[13]  M. Furione,et al.  Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  D. Lilleri,et al.  Polyfunctional Analysis of Human Cytomegalovirus (HCMV)-Specific CD4+ and CD8+ Memory T-Cells in HCMV-Seropositive Healthy Subjects Following Different Stimuli , 2014, Journal of Clinical Immunology.

[15]  F. Baldanti,et al.  Kinetics of human cytomegalovirus (HCMV) DNAemia in transplanted patients expressed in international units as determined with the Abbott RealTime CMV assay and an in-house assay. , 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  D. Lilleri,et al.  Human cytomegalovirus-specific CD4(+) and CD8(+) T-cell response determination: comparison of short-term (24h) assays vs long-term (7-day) infected dendritic cell assay in the immunocompetent and the immunocompromised host. , 2010, Clinical immunology.

[17]  F. Rovida,et al.  Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients , 2006, Journal of medical virology.

[18]  S. Riddell,et al.  Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. , 2003, Blood.

[19]  S. Wolff.  Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation , 2002, Bone Marrow Transplantation.

[20]  S. Riddell,et al.  Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. , 1994, Blood.